Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer

OBJECTIVES: * To compare the PSA response rate in patients with hormone-independent recurrent or metastatic adenocarcinoma of the prostate treated with bicalutamide and everolimus after first-line androgen deprivation therapy. * To evaluate the time to treatment failure and overall survival of these patients. * To assess the toxicity of bicalutamide and everolimus in these patients. OUTLINE: Patients are stratified according to disease status (metastatic disease vs biochemical recurrence without measurable disease). Patients receive oral bicalutamide and oral everolimus once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 28-42 days and then every 3 months thereafter.